Classification of IDH wild-type glioblastoma tumorspheres into low- and high-invasion groups based on their transcriptional program

• Published in: British journal of cancer Vol. 129; no. 7; pp. 1061 - 1070
• Main Authors: Park, Junseong, Shim, Jin-Kyoung, Lee, Mirae, Kim, Dokyeong, Yoon, Seon-Jin, Moon, Ju Hyung, Kim, Eui Hyun, Park, Jeong-Yoon, Chang, Jong Hee, Kang, Seok-Gu
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 19.10.2023; Nature Publishing Group UK
• Subjects: Brain cancer; Genotype & phenotype; Glioblastoma; Invasiveness; Medical prognosis; Metastases; Phenotypes; Prognosis; Proteomes; siRNA; Stat3 protein; Transcription factors; Transcriptomes; Tumors
• DOI: 10.1038/s41416-023-02391-y
• ISSN: 0007-0920

Glioblastoma (GBM), one of the most lethal tumors, exhibits a highly infiltrative phenotype. Here, we identified transcription factors (TFs) that collectively modulate invasion-related genes in GBM. The invasiveness of tumorspheres (TSs) were quantified using collagen-based 3D invasion assays. TF activities were quantified by enrichment analysis using GBM transcriptome, and confirmed by cell-magnified analysis of proteome imaging. Invasion-associated TFs were knocked down using siRNA or shRNA, and TSs were orthotopically implanted into mice. After classifying 23 patient-derived GBM TSs into low- and high-invasion groups, we identified active TFs in each group-PCBP1 for low invasion, and STAT3 and SRF for high invasion. Knockdown of these TFs reversed the phenotype and invasion-associated-marker expression of GBM TSs. Notably, MRI revealed consistent patterns of invasiveness between TSs and the originating tumors, with an association between high invasiveness and poor prognosis. Compared to controls, mice implanted with STAT3- or SRF-downregulated GBM TSs showed reduced normal tissue infiltration and tumor growth, and prolonged survival, indicating a therapeutic response. Our integrative transcriptome analysis revealed three invasion-associated TFs in GBM. Based on the relationship among the transcriptional program, invasive phenotype, and prognosis, we suggest these TFs as potential targets for GBM therapy.